Los Angeles Capital Management LLC raised its holdings in Organon & Co. (NYSE:OGN - Free Report) by 47.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 259,831 shares of the company's stock after purchasing an additional 83,510 shares during the period. Los Angeles Capital Management LLC owned about 0.10% of Organon & Co. worth $4,971,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently modified their holdings of the business. River Global Investors LLP grew its position in Organon & Co. by 4.8% in the 3rd quarter. River Global Investors LLP now owns 58,775 shares of the company's stock valued at $1,124,000 after acquiring an additional 2,711 shares in the last quarter. Crossmark Global Holdings Inc. increased its stake in Organon & Co. by 43.4% in the third quarter. Crossmark Global Holdings Inc. now owns 20,157 shares of the company's stock valued at $385,000 after purchasing an additional 6,096 shares during the period. Acorn Financial Advisory Services Inc. ADV acquired a new position in Organon & Co. in the 3rd quarter valued at about $743,000. CWA Asset Management Group LLC purchased a new stake in shares of Organon & Co. during the third quarter worth approximately $355,000. Finally, Philip James Wealth Mangement LLC purchased a new stake in shares of Organon & Co. in the third quarter valued at about $15,386,000. 77.43% of the stock is owned by hedge funds and other institutional investors.
Organon & Co. Stock Down 3.4 %
NYSE:OGN traded down $0.54 on Tuesday, hitting $15.55. The stock had a trading volume of 1,851,272 shares, compared to its average volume of 2,242,357. The company has a quick ratio of 1.17, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The business's fifty day moving average is $18.63 and its 200 day moving average is $20.05. Organon & Co. has a 52 week low of $10.84 and a 52 week high of $23.10. The company has a market cap of $4.00 billion, a PE ratio of 3.19, a P/E/G ratio of 0.75 and a beta of 0.84.
Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.03). Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The firm had revenue of $1.58 billion for the quarter, compared to analysts' expectations of $1.56 billion. During the same period in the prior year, the business posted $0.78 EPS. The business's quarterly revenue was up 4.1% compared to the same quarter last year. On average, equities research analysts expect that Organon & Co. will post 3.89 EPS for the current fiscal year.
Organon & Co. Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Tuesday, November 12th will be paid a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a yield of 7.20%. The ex-dividend date of this dividend is Tuesday, November 12th. Organon & Co.'s dividend payout ratio (DPR) is presently 22.22%.
Wall Street Analysts Forecast Growth
OGN has been the subject of a number of recent research reports. JPMorgan Chase & Co. downgraded shares of Organon & Co. from a "neutral" rating to an "underweight" rating and lifted their price target for the stock from $18.00 to $20.00 in a report on Friday, September 6th. Evercore ISI raised Organon & Co. to a "strong-buy" rating in a report on Wednesday, September 18th.
Get Our Latest Report on Organon & Co.
About Organon & Co.
(
Free Report)
Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.
Featured Articles
Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.